Profiling APOL1 Nephropathy Risk Variants in Genome-Edited Kidney Organoids with Single-Cell Transcriptomics

• Published in: Kidney360 Vol. 1; no. 3; pp. 203 - 215
• Main Authors: Liu, Esther, Radmanesh, Behram, Chung, Byungha H, Donnan, Michael D, Yi, Dan, Dadi, Amal, Smith, Kelly D, Himmelfarb, Jonathan, Li, Mingyao, Freedman, Benjamin S, Lin, Jennie
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.03.2020
• Subjects: Apolipoprotein L1 - genetics; Endothelial Cells - metabolism; Humans; Induced Pluripotent Stem Cells - metabolism; Kidney; Kidney Diseases - genetics; Organoids - metabolism; Original Investigations; Transcriptome - genetics
• ISSN: 2641-7650; 2641-7650
• DOI: 10.34067/KID.0000422019

DNA variants in associate with kidney disease, but the pathophysiologic mechanisms remain incompletely understood. Model organisms lack the gene, limiting the degree to which disease states can be recapitulated. Here we present single-cell RNA sequencing (scRNA-seq) of genome-edited human kidney organoids as a platform for profiling effects of risk variants in diverse nephron cell types. We performed footprint-free CRISPR-Cas9 genome editing of human induced pluripotent stem cells (iPSCs) to knock in high-risk G1 variants at the native genomic locus. iPSCs were differentiated into kidney organoids, treated with vehicle, IFN- , or the combination of IFN- and tunicamycin, and analyzed with scRNA-seq to profile cell-specific changes in differential gene expression patterns, compared with isogenic G0 controls. Both G0 and G1 iPSCs differentiated into kidney organoids containing nephron-like structures with glomerular epithelial cells, proximal tubules, distal tubules, and endothelial cells. Organoids expressed detectable only after exposure to IFN- . scRNA-seq revealed cell type-specific differences in G1 organoid response to induction. Additional stress of tunicamycin exposure led to increased glomerular epithelial cell dedifferentiation in G1 organoids. Single-cell transcriptomic profiling of human genome-edited kidney organoids expressing risk variants provides a novel platform for studying the pathophysiology of APOL1-mediated kidney disease.